INVOKANA^® (canagliflozin) cardiovascular (CV) protection in T2D

Prescribing Information can be found under Useful Links

Invokana^®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
in addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.

The addition of INVOKANA to standard of care reduced the risk of major adverse cardiovascular events (MACE) vs placebo.^4,5

CANVAS Program⁵

The CANVAS Program consisted of two double-blind randomised trials, that assessed canagliflozin vs placebo in participants with T2D who were at high risk of CV events. Canagliflozin 100mg to 300mg daily on a background of standard of care treatments for glycaemic management and control of other risk factors, e.g. atherosclerotic cardiovascular disease.

CREDENCE⁴

CREDENCE is the first study involving an SGLT2 inhibitor, dedicated to renal outcomes patients with T2D. Canagliflozin 100mg daily on a background of standard of care treatments for glycaemic management, control of other risk factors, and stable maximally tolerated RAS-blockade (e.g. angiotensin converting enzyme or angiotensin receptor blockers).

Invokana-Diagram-11

MACE (composite endpoint)

Major
Averse
Cardiovascular
Event

CANVAS Program⁵

(HR 0.86; 95% Cl,0.75-0.97; P<0.001 for non-inferiority, P=0.02 for superiority) NNT (3.0 years): 79 (95% CI, not stated)⁵

CREDENCE⁴

(HR 0.80; 95% Cl, 0.67-0.95; P=0.01) NNT (2.5 years): 40 (95% CI, 23-165)⁴

-20%-Blue-Circle

Invokana-Diagram-12

CANVAS Program⁵

(HR 0.67; 95% Cl, 0.52-0.87; nominal significance; exploratory endpoint) NNT (3 years): 106 (95% CI, not stated)⁵

CREDENCE⁴

(HR 0.61; 95% Cl, 0.47-0.80; P<0.001) NNT (2.5 years): 46(95% CI, 29-124) ⁴

-33%-Red-Circle

Abbreviations:
CI – Confidence Interval
HR – Hazard Ratio
MACE – Major adverse cardiovascular events
NNT – Number Needed to Treat
CV-Cardiovascular
RRR - Relative Risk Reduction

PP-IN-UK-0237 July 2023

INVOKANA® (canagliflozin) cardiovascular (CV) protection in T2D

The addition of INVOKANA to standard of care reduced the risk of major adverse cardiovascular events (MACE) vs placebo.4,5

CANVAS Program5

CREDENCE4

MACE (composite endpoint)

CANVAS Program5

CREDENCE4

CANVAS Program5

CREDENCE4

INVOKANA^® (canagliflozin) cardiovascular (CV) protection in T2D

The addition of INVOKANA to standard of care reduced the risk of major adverse cardiovascular events (MACE) vs placebo.^4,5

CANVAS Program⁵

CREDENCE⁴

CANVAS Program⁵

CREDENCE⁴

CANVAS Program⁵

CREDENCE⁴